Published on
02:05 GMT
[Reporter's Notebook] FDA staff exodus may spark delays, cost burden for Korean drugmakers
“Indeed, the clinical review period has been delayed, and we're considering whether to relocate our production base to the U.S.” This is what a Korean drugmaker official recently told this reporter. The company is conducting clinical trials in the U.S …
Source:
Korea Biomedical Review
-
Neutral
